What is William Blair’s Forecast for TNYA FY2024 Earnings?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – William Blair lifted their FY2024 earnings per share (EPS) estimates for shares of Tenaya Therapeutics in a report released on Wednesday, November 6th. William Blair analyst S. Corwin now anticipates that the company will post earnings of ($1.36) per share for the year, up from their prior forecast of ($1.38). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.40) per share. William Blair also issued estimates for Tenaya Therapeutics’ Q4 2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.39) EPS and FY2026 earnings at ($1.58) EPS.

TNYA has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a report on Friday, October 18th. Piper Sandler reaffirmed an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Canaccord Genuity Group reiterated a “buy” rating and issued a $16.00 target price on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital lowered their price target on shares of Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $14.75.

Tenaya Therapeutics Stock Performance

NASDAQ TNYA opened at $2.21 on Monday. The company’s 50-day simple moving average is $2.04 and its two-hundred day simple moving average is $3.01. Tenaya Therapeutics has a one year low of $1.61 and a one year high of $7.01. The company has a market capitalization of $174.34 million, a price-to-earnings ratio of -1.67 and a beta of 2.34.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07.

Insider Activity

In other news, CEO Faraz Ali sold 9,748 shares of Tenaya Therapeutics stock in a transaction on Friday, August 16th. The shares were sold at an average price of $2.89, for a total transaction of $28,171.72. Following the completion of the sale, the chief executive officer now directly owns 188,331 shares in the company, valued at approximately $544,276.59. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 19,539 shares of company stock worth $56,468 over the last 90 days. 32.76% of the stock is currently owned by corporate insiders.

Institutional Trading of Tenaya Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. The Manufacturers Life Insurance Company raised its holdings in shares of Tenaya Therapeutics by 43.2% during the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after purchasing an additional 7,000 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Tenaya Therapeutics by 10.5% during the 2nd quarter. Rhumbline Advisers now owns 78,160 shares of the company’s stock valued at $242,000 after buying an additional 7,441 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Tenaya Therapeutics by 27.7% in the 2nd quarter. American Century Companies Inc. now owns 102,114 shares of the company’s stock valued at $317,000 after buying an additional 22,146 shares during the period. Algert Global LLC purchased a new stake in shares of Tenaya Therapeutics in the second quarter worth about $74,000. Finally, SG Americas Securities LLC acquired a new stake in Tenaya Therapeutics during the third quarter worth about $49,000. 90.54% of the stock is currently owned by institutional investors and hedge funds.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.